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Congenital diarrhoeal disorders: advances in 
this evolving web of inherited enteropathies
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Abstract | Congenital diarrhoeal disorders (CDDs) represent an evolving web of rare chronic enteropathies, 
with a typical onset early in life. In many of these conditions, severe chronic diarrhoea represents the primary 
clinical manifestation, whereas in others diarrhoea is only a component of a more complex multi-organ 
or systemic disorder. Typically, within the first days of life, diarrhoea leads to a life-threatening condition 
highlighted by severe dehydration and serum electrolyte abnormalities. Thus, in the vast majority of cases 
appropriate therapy must be started immediately to prevent dehydration and long-term, sometimes severe, 
complications. The number of well-characterized disorders attributed to CDDs has gradually increased over 
the past several years, and many new genes have been identified and functionally related to CDDs, opening 
new diagnostic and therapeutic perspectives. Molecular analysis has changed the diagnostic scenario in 
CDDs, and led to a reduction in invasive and expensive procedures. Major advances have been made in terms 
of pathogenesis, enabling a better understanding not only of these rare conditions but also of more common 
diseases mechanisms.
Berni Canani, R. et al. Nat. Rev. Gastroenterol. Hepatol. advance online publication 17 March 2015; doi:10.1038/nrgastro.2015.44
Introduction
Congenital diarrhoeal disorders (CDDs) are a group of 
rare enteropathies characterized by a heterogeneous aeti-
ology with a typical early onset of symptoms. They are 
generally monogenic disorders inherited in an autosomal 
recessive manner.1 CDDs are challenging to treat because 
of the severity of the clinical picture and the broad range 
of disorders in differential diagnosis.1 Abnormal fluid 
transport might begin in utero, manifesting as maternal 
polyhydramnios. Then, soon after birth, patients usually 
present with severe diarrhoea that typically, within a few 
days, leads to severe dehydration and serum electrolyte 
imbalance. In the vast majority of cases patients require 
hospitalization and a prompt diagnosis.1 The more severe 
forms of CDDs produce life-threatening chronic diar-
rhoea with massive loss of fluids and intestinal failure 
requiring long-term parenteral nutrition. They are 
associated with substantial mortality and morbidity 
and many patients undergo intestinal transplantation 
procedures.1 Rare, mild forms with subtle clinical signs 
might remain undiagnosed until adulthood, by which 
time patients have developed irreversible complications, 
as observed in some patients with congenital chloride 
diarrhoea who develop renal dysfunction and gout as a 
consequence of a chronic contraction of the intravascular 
space.2 Some CDDs can be treated with dietary modifi-
cation, but in many cases chronic nutritional support is 
required. The exact prevalence of CDDs remains to be 
established; it differs among populations and geographi-
cal areas. A study from the Italian Society of Pediatric 
Gastroenterology, Hepatology, and Nutrition estimated 
that autoimmune enteropathy and microvillus inclusion 
disease (MVID) are the most common causes of CDDs.3
Diarrhoea can be the result of secretory and/or osmotic 
or inflammatory mechanisms.4 Secretory diarrhoea is char-
acterized by an increased electrolyte and water flux towards 
the intestinal lumen, resulting from either inhibition of 
sodium chloride (NaCl) absorption by villous enterocytes 
or an increase in chloride ion (Cl–) secretion by epithelial 
cells in the crypts.4 An example of a predominant secre-
tory diarrhoea is MVID.5 Osmotic diarrhoea is caused by 
the presence of nonassimilated nutrients in the gut, which 
drives fluid into the lumen via osmotic forces.4 An example 
of a pure form of osmotic diarrhoea is glucose–galactose 
malabsorption, in which the unabsorbed monosaccharide 
reaching the colon results in diarrhoea.6 Inflammatory 
diarrhoea is caused by dysregulation of the immune system 
leading to inflammatory infiltration and damage to the 
gut mucosa, as observed in auto immune enteropathy or 
in immune dysregulation p olyendocrinopathy enteropathy 
X-linked (IPEX) syndrome.
Evaluation of CDDs includes understanding the basic 
mechanism(s) responsible for disease. However, the 
increasing number of conditions included within the 
CDDs group—together with the fact that different con-
ditions could be characterized by the same mechanism 
or that different mechanisms could overlap in the same 
patient—might limit this approach. Evolving knowledge of 
the pathogenesis of CDDs suggests the utility of a classifi-
cation system based on the main pathogenetic mechanism, 
which could help the approach to these patients (Figure 1). 
This classification comprises four groups of disorders: one, 
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defects in digestion and absorption of nutrients and elec-
trolytes; two, defects in enterocyte structure; three, defects 
in enteroendocrine cell differentiation; and four, defects in 
intestinal immune-related homeostasis. This Review high-
lights new CDD entities and advances understanding of 
functionally related genes that are opening new diagnostic 
and therapeutic perspectives.
Defects in digestion and absorption
This group includes the most abundant number of 
CDDs. They are conditions in which a defect in one 
of the main mechanisms of digestion or transport of 
Key points
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nutrients and electrolytes leads to chronic diarrhoea. 
The prototypes of this group are glucose–galactose mal-
absorption and congenital chloride diarrhoea,7,8 but new 
conditions have been described. No histological or ultra-
structural defects are generally observed in these patients 
at the gut level (Table 1).
Familial diarrhoea syndrome
This condition has been described in 32 members of a 
Norwegian family, and is characterized by early-onset 
chronic diarrhoea and meteorism (also known as tym-
panites). Abdominal pain, dysmotility and IBD have been 
described in a subset of patients.9 All affected members 
have a heterozygous missense mutation (p.Ser840Ile) in 
the GUCY2C gene, which encodes the intestinal gua-
nylate cyclase receptor for uroguanylin, guanylin and 
heat-stable enterotoxins. Although this gain-of-function 
variant increases ligand-mediated activation of guanylate 
cyclase and intracellular cyclic guanosine monophosphate 
(cGMP) levels, basal levels are comparable to the wild-
type receptor.9 Elevated cGMP levels results in activation 
of protein kinase GII, leading to phosphorylation of the 
cystic fibrosis transmembrane conductance regulator 
(CFTR) channel.10 This phosphorylation leads to severe 
chronic secretory diarrhoea deriving from an efflux of Cl– 
and water into the intestinal lumen, with reduced sodium 
ion (Na+) absorption owing to inhibition of the Na+–H+ 
exchanger 3 (NHE3).11
DGAT1-deficiency-related diarrhoea
A rare null mutation in DGAT1 (which encodes acyl 
CoA:diacylglycerol acyltransferases 1) has been reported 
in two infants, resulting in a CDD and protein losing 
enteropathy.12 DGATs catalyse the final step of trigly-
ceride synthesis. DGAT1 is expressed ubiquitously, with 
highest expression in the gut. Animal models lacking 
DGAT1 have delayed fat absorption with more fat reach-
ing the distal gut. However, how DGAT1 deficiency 
causes diarrhoea and protein losing enteropathy is still 
unclear. A possible explanation could be the toxic role of 
excess diacylglycerols or fatty acids, which might act as 
bioactive signalling lipids or via a detergent-like action.12
Defects in enterocyte structure
Typical histological and ultrastructural hallmarks charac-
terize this group of severe disorders that includes two main 
conditions: MVID,13,14 and congenital tufting enteropathy 
(CTE).15 Syndromic diarrhoea, also known as phenotypic 
diarrhoea or tricho-hepato-enteric syndrome (THE), is 
commonly included in this group, and is characterized by 
a wide range of histological damage16 (Table 2). Progresses 
in managing patients with parenteral nutrition and intes-
tinal transplantation have reduced the mortality rate of 
these conditions. Nevertheless, advances in genetics open 
new perspectives in understanding their mechanisms and 
in the clinical approach.
Microvillus inclusion disease
The pathognomonic characteristic of MVID is loss of the 
apical brush border and the formation of intracellular 
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Figure 1 | The evolving knowledge in congenital diarrhoeal disorders 
pathogenesis suggests a new classification that could help the therapeutic 
approach to these conditions.
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microvillus inclusions. These microvillus inclusions are 
observed in ~10% of enterocytes at the villus tips, whereas 
normal brush borders are often present on the enterocytes 
in the proximal part of the villus.17 These findings suggest 
that microvilli are formed initially and that stabilization 
of initial cell polarity might represent a future target for 
therapy in MVID. Most patients with early-onset MVID 
display inactivating mutations in myosin Vb (MYO5B).18 
MYO5B works as a dynamic tether for specific RAB small 
GTPases (RAB8A, RAB10, and RAB11) maintaining 
these proteins at their appropriate subapical membrane 
localization. This interaction is crucial to maintain normal 
intestinal epithelial cell polarity, apical trafficking and 
microvilli growth. Alterations in this interaction, deriving 
from mutations in MYO5B, lead to a mucosa with decre-
ments in absorptive pathways and a leaky epithelium at 
the villus tips, which causes alterations in both intercellular 
junctions and ion transport pathways necessary for adapta-
tion through transcellular pumps and channels.19,20 These 
concepts have been supported by the findings of Knowles 
et al.;17 using a cellular model of MVID, they demonstrated 
that loss or mutation in MYO5B causes uncoupling of RABs 
from MYO5B with an abnormal localization of RAB8A 
and RAB11A throughout the cytoplasm.17 Uncoupling of 
Table 1 | Defects in absorption and transport of nutrients and electrolytes: genetics and epidemiology
Disease Inheritance and incidence Gene
(OMIM number)
Impaired biological activity causing diarrhoea 
and involved protein
Abetalipoproteinaemia AR
150 cases described
MTTP (157147) Impaired microsomal triglyceride transfer protein 
activity, lower synthesis of VLDL and reduced 
absorption of lipids
Acrodermatitis 
enteropathica
AR
1:500,000
SLC39A4 
(607059)
Impaired duodenal and jejunum Zn2+ transport 
by solute carrier family 39 member 42
Chylomicron retention 
disease
AR
40 cases described
SAR1B  
(607690)
Impaired chylomicron transport within enterocytes 
owing to the altered activity of a small GTPase
Congenital chloride 
diarrhoea
AR 
Common in Finland, Poland, 
Persian Gulf; few hundred cases 
in other ethnic groups
SLC26A3
(126650)
Impaired ileal and colonic Cl–/HCO3
– exchange 
owing to the impaired activity of solute carrier 
family 26 member 3
Congenital lactase 
deficiency
AR 
1:60,000 in Finland; few hundred 
cases in other ethnic groups
LCT (603202) Reduced brush border Lactase-phlorizin 
hydrolase activity
Congenital sodium 
diarrhoea*
AR 
Few cases described
SPINT2* 
(605124)
Impaired jejunal Na+/H+ exchange due to the 
reduced activity of serine peptidase inhibitor 
Kunitz type 2
Diarrhoea associated 
DGAT1 mutation
AR 
One Ashkenazi family described
DGAT1 
(604900)
Impaired activity of diacylglycerol acyltransferase 1; 
unknown effect
Enterokinase deficiency AR 
Few cases described
TMPRSS15 
(606635)
Impaired activation of trypsinogen by 
transmembrane protease serine 15
Familial diarrhoea 
syndrome
AR 
One family described
GLUCY2C 
(601330)
Increased activity of guanylate cyclase 2C enhances 
levels of cGMP, hyperactivating intestinal cystic 
fibrosis transmembrane conductance regulator
Fanconi–Bickel syndrome AR 
Few hundred cases described
SLC2A2 
(138160)
Impaired activity of solute carrier family 2 member 2 
(facilitative glucose carrier) in hepatocytes, 
pancreatic beta cells and enterocytes
Glucose–galactose 
malabsorption
AR 
Few hundred cases described
SLC5A1 
(182380)
Impaired sodium-coupled enterocyte absorption 
of glucose and galactose due to reduced 
activity of solute carrier family 5 member 1
Hypobetalipoproteinaemia Autosomal co-dominant 
1:1,000–1:3,000
ApoB (107730) Impaired apolipoprotein B structure and stability 
and consequent reduced absorption of lipids
Lysinuric protein 
intolerance
AR 
Few hundred cases described
SLC7A7 
(603593)
Impaired amino acid transport due to altered 
light chain of the solute carrier family 7 member 7
Maltase–glucoamylase 
deficiency
AR 
Few cases described
MGAM 
(154360)
Reduced maltase–glucoamylase activity (which 
might be combined with the deficient activity of 
other brush border enzymes)
Primary bile acid 
diarrhoea‡
AR 
Few cases described
SLC10A2 
(601295)
Reduced enterohepatic reabsorption of bile 
acids by solute carrier family 10 member 2
Sucrase-isomaltase 
deficiency
AR 
1:5,000; higher in Greenland, 
Alaska and Canada
SI
(609845)
Reduced brush border sucrase and/or 
isomaltase activity
*Analysis of the intestinal brush border membrane of affected patients revealed that the condition is caused by a functional defect in one of the Na+/H+ 
exchangers localized to the apical membrane of small intestinal epithelial cells. However, no mutations were detected in the genes encoding any of the  
Na+/H+ exchangers identified so far (NHE1, NHE2, NHE3, and NHE5)72 ‡In adults, an alteration of the normal regulatory mechanisms in the synthesis of bile 
acids, mediated by fibroblast growth factor 19 (FGF-19), has been found as a main cause of bile acid diarrhoea.73 Abbreviation: AR, autosomal recessive.
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MYO5B from RAB8A promotes loss of microvilli, and a 
loss of interactions between RAB11A and MYO5B results 
in formation of microvillus inclusions.
Why MVID mutations lead to an enterocyte-specific 
effect as opposed to more global effects is poorly under-
stood, given that other highly polarized epithelial tissues 
seem unaffected by the disease. In vertebrates, three iso-
forms of myosin V are recognized: MYO5A; MYO5B; 
and MYO5C.21 All these isoforms can interact with RAB10 
and RAB8A, but only MYO5A and MYO5B can bind to 
RAB11 family members.21 One possible explanation for the 
severity of the intestinal features in patients with MVID is 
that MYO5A might compensate for the loss of MYO5B in 
other polarized cell types and that low levels of MYO5A 
in enterocytes make intestinal epithelial cells more vul-
nerable to loss or mutation of MYO5B.20 Moreover, the 
mechanisms for establishing apical microvillar specializa-
tions might differ in different polarized epithelial cells.20 
In addition to chronic unremitting diarrhoea, patients 
with MVID can also develop cholestatic liver disease that 
worsens after intestinal transplantation. The origin of this 
condition has been related to altered MYO5B–RAB11A 
interaction, defective bile salt export pump in hepatocytes, 
and increased ileal bile acid absorption.22
Whole-exome sequencing of DNA from patients 
with MVID who have milder clinical phenotypes per-
mitting partial or complete weaning from parenteral 
nutrition, showed homozygous truncating mutations in 
an apically targeted N-ethylmaleimide-sensitive factor 
attachment protein receptor (SNARE) named syntaxin 3 
(STX3).5 Syntaxin 3 acts as a regulator of protein traf-
ficking, vesicle fusion and exocytosis, and exerts a 
pivotal role in cell polarity in the intestine, liver, kidney 
and stomach.5 Interestingly, patients with mutations in 
syntaxin 3 binding protein 2 (STXBP2) causing famil-
ial haemophagocytic lymphohistiocytosis type 5, have 
micro villus atrophy with clinical and histological f indings 
similar to MVID.23
Congenital tufting enteropathy
Patients affected by CTE show typical epithelial tufts that 
can be present from the duodenum to the large intestine. 
The disorder has been linked to mutations in the epithe-
lial cell adhesion molecule gene (EPCAM). The EPCAM 
expression pattern varies along the crypt–villus axis, with 
highest expression in the crypt epithelial and a decline in 
cells expressing this protein at the top of the villi. EPCAM 
does not localize to the apical membrane, but is abun-
dant along the basolateral membranes where it regulates 
cellular adhesion and proliferation.24 EpCAM is thus a 
pleiotropic molecule with an important role in initiation, 
development, maintenance, repair and in the function-
ing of gut epithelia. In patients with CTE, the phenotype 
associated with mutations of EPCAM gene is usually 
characterized by isolated diarrhoea without associated 
extraintestinal symptoms, except for late-onset arthritis 
in a subgroup of patients.25
A second group of individuals with CTE characterized 
by mutations in SPINT2 (which encodes kunitz-type pro-
tease inhibitor 2 [also known as hepatocyte growth factor 
activator inhibitor type 2, HAI-2]) have been identified. 
As with EpCAM, HAI-2 is a transmembrane protein.25 
This potent serine protease inhibitor is involved in epithe-
lial regeneration, as well as in the NF-κB and transform-
ing growth factor (TGF)-β signalling pathways. Children 
with SPINT2 variants present with a syndromic form of 
CTE, characterized by chronic diarrhoea, associated 
with superficial punctate keratitis and choanal atresia, 
as well as other sporadic abnormalities. These different 
but overlapping enterocyte abnormalities suggest that the 
two disease-associated genes belong to distinct pathways 
both regulating cell adhesion and cytoskeleton dynamics 
leading to the CTE phenotype.25
Tricho-hepato-enteric syndrome
Patients with THE (also known as syndromic diarrhoea) 
present with chronic diarrhoea, facial dysmorphism and 
Table 2 | Defects in enterocyte structure: genetics and epidemiology
Disease Inheritance and incidence Gene
(OMIM number)
Impaired biological activity causing diarrhoea 
and involved protein
Congenital tufting 
enteropathy*
AR 
1:50,000–100,000; higher 
among Arabians
EPCAM
(185535)
Defective activity of epithelial cell adhesion 
molecule causes the altered cell–cell adhesion
12 patients described SPINT2
(605124)
Impaired activity of serine peptidase inhibitor Kunitz 
type 2, which is involved in epithelial regeneration
Microvillous inclusion 
disease
AR 
Few cases described; higher 
frequency among Navajo
MYO5B
(606540)
Reduced activity of myosin 5B causes abnormal 
recycling of endosomes
AR 
Two patients described
STX3
(600876)
Impaired activity of syntaxin 3, which is involved 
in membrane fusion of apical vesicles
Trichohepatoenteric 
syndrome
(syndromic diarrhoea)
AR 
Few cases described
TTC37
(614589)
Impaired synthesis or localization of brush border 
transporters due to the reduced activity of 
tetra-trico-peptide repeat domain 37
AR 
Few cases described
SKIV2L
(600478)
Unknown mechanism due to the impaired activity 
of SKI2W helicase
*Congenital tufting enteropathy associated with an EPCAM mutation is characterized by only intestinal involvement, whereas a mutation in SPINT2 leads to 
a syndromic form with dysmorphic features, woolly hair, small birth weight and immune deficiency and diarrhoea with high sodium content in the stools. 
Abbreviation: AR, autosomal recessive.
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hair abnormalities, which might or might not be associ-
ated with other signs or symptoms, such as intrauterine 
growth retardation, immunodeficiency, skin abnormali-
ties, liver disease, congenital cardiac defects and plate-
let anomalies.16 Moderate to severe villus atrophy with 
inconstant infiltration of mononuclear cells characterizes 
the histological picture. THE is caused by a mutation in 
TTC37 in 60% of cases and SKIV2L in 40% of the cases.26 
No genotype–phenotype correlation can be made either 
with the causative gene (TTC37 or SKIV2L) or the muta-
tion type. TTC37 (tetratricopeptide repeat protein 37; also 
called Ski3) is expressed in many tissues, including vascu-
lar endothelium, lung and intestine, but not in the liver.26 
TTC37 (Ski3) is a key component of the SKI complex, a 
multiprotein complex required for exosome-mediated 
RNA surveillance.26 Subsequently, mutations in SKIV2L 
in a group of six individuals affected by typical THE syn-
drome, but negative for TTC37 mutations, have been 
described.27 The mutation types suggest that the disease 
mechanism is SKIV2L loss-of-function of a cytoplasmic 
exosome cofactor involved in various mRNA decay path-
ways and required for normal cell growth.27 The mecha-
nism by which mRNA surveillance defects lead to various 
clinical symptoms needs further investigation.16
Defects in enteroendocrine cell differentiation
These conditions are characterized by abnormal enter-
oendocrine cell development or function and manifest 
as pure forms of congenital osmotic diarrhoea, associ-
ated or not with other systemic endocrine abnormalities. 
The common feature of this group of CDDs is that the 
genes encode either transcription factors that generate 
all or a subset of enteroendocrine cells, or an endopepti-
dase expressed in all endocrine cells, which is there-
fore required for the production of all active hormones 
(Table 3). Various knockout mouse models of each of 
these genes are associated with early postnatal mortality 
and occasionally diarrhoea.28–30 Four genes are involved in 
this group of CDDs: NEUROG3; RFX6; ARX; and PCSK1.
Enteric anendocrinosis
Studies in knockout mouse models have demonstrated 
that neurogenin-3 (encoded by NEUROG3; a basic helix-
loop-helix transcription factor) is required and sufficient 
to drive the development of enteroendocrine cells and 
β-cells in pancreatic islets.31 Children with neurogenin-3 
deficiency present with a severe paucity of enteroendo-
crine cells (enteric anendocrinosis), and also develop 
insulin-dependent diabetes mellitus in early childhood, 
but not other endocrine abnormalities.32
Mitchell–Riley Syndrome
Homozygous mutations of RFX6 are associated with a 
complex clinical phenotype (Mitchell–Riley syndrome) 
highlighted by duodenal atresia, biliary abnormalities, 
neonatal diabetes mellitus and malabsorptive diar-
rhoea.28 DNA-binding protein RFX6 (also known as 
regulatory factor X 6; encoded by RFX6) is a winged-
helix transcription factor that is downstream of neuro-
genin-3 and is required for islet cell development and 
enteroendocrine cell function.33 Unlike in children with 
neurogenin-3 deficiency, mutation of RFX6 is associated 
with normal enteroendocrine cell number. The intesti-
nal atresia associated with RFX6 mutations is probably 
related to a not yet fully characterized role of RFX6 in 
the early gut endoderm. Furthermore, although mouse 
studies suggest that DNA-binding protein RFX6 is exclu-
sively expressed in enteroendocrine K-cells that express 
gastric inhibitory polypeptide and others hormones, it 
remains uncertain if this subset of cells is depleted in 
humans with DNA-binding protein RFX6 deficiency.34
Other defects of enteroendocrine cell differentiation
Mutations in the ARX gene—which encodes homeobox 
protein ARX (also known as aristaless-related homeobox), 
a paired homeodomain transcription factor—are associ-
ated with a complex clinical phenotype of X-linked mental 
retardation, seizures, lissencephaly, abnormal genitalia 
and occasionally congenital diarrhoea.35 The ARX gene 
is a downstream target of neurogenin-3 and is expressed 
in a subset of enteroendocrine cells, including those that 
express cholecystokinin, secretin and glucagon.29 More 
than 50% of patients with loss-of-function ARX muta-
tions have a polyalanine expansion that might account 
for the highly variable neurological and intestinal clinical 
p henotypes that are associated with this disorder.36
All functional hormones produced by endocrine cells, 
including those in the gut, are processed by a specific 
Ca2+-dependent serine endoprotease named proprotein 
convertase 1/3 (PC1/3; also known as neuroendocrine 
Table 3 | Defects in enteroendocrine cell differentiation: genetics and epidemiology
Disease Inheritance and 
incidence
Gene
(OMIM number)
Impaired biological activity causing diarrhoea and 
involved protein
Enteric anendocrinosis AR 
Few cases described
NEUROG3 
(604882)
Altered neurogenin-3, which regulates the development of gut 
epithelial cells into endocrine cells
Mitchell–Riley 
Syndrome
AR 
Few cases described
RFX6
(612659)
Reduced activity of regulatory factor X6 involved in pancreatic 
morphogenesis and development
Proprotein convertase 
1/3 deficiency
AR 
Few cases described
PCSK1 (162150) Reduced activity of proprotein convertase 1/3 involved in the 
activation of prohormones produced by enteroendocrine cells
X-linked lissencephaly 
and MR
X-linked 
Few hundred cases 
described
ARX
(300382)
Impaired activity of aristaless related homeobox 
transcriptional factor, which regulates enteroendocrine cell 
development
Abbreviation: AR, autosomal recessive.
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convertase 1) that converts prohormones into their bio-
active form.30 Homozygote loss-of-function mutations 
in PCSK1 (which encodes PC1/3) have been associated 
with malabsorptive diarrhoea and other endocrinopa-
thies including adrenal insufficiency, hypothyroidism 
and hypogonadism.37,38 PC1/3 is also expressed in the 
hypothalamic region that produces various central orexi-
genic hormones that control appetite, and children with 
mutations in PCSK1 are extremely polyphagic. In a cohort 
of children with this disorder (enteric dysendocrinosis), 
severe failure to thrive was commonly found, and paren-
teral nutrition was required for the first several years of 
life.39–41 Interestingly, polyphagia induced by abnormalities 
in central processing of components of the leptin signal-
ling pathway results in moderate obesity beyond the first 
several years of life despite chronic diarrhoea. These chil-
dren also develop diabetes insipidus and growth hormone 
deficiency, which distinguishes PCSK1 deficiency from 
other enteric endocrinopathies. These findings suggest 
that enteric hormones might be particularly important to 
facilitate nutrient absorption during infancy when caloric 
requirement (per body weight) is at its highest.
Defects in intestinal immune homeostasis
Mutations in genes encoding proteins with relevant func-
tions in intestinal immune-related homeostasis can result 
in early-onset chronic diarrhoea. In these CDDs, diar-
rhoea can derive from three main mechanisms: altered 
immune response against pathogens, inflammation or 
lack of immune regulation. Depending on the type of 
underlying immunological defect, the three mechanisms 
can variably contribute to clinical and histological mani-
festations. Predominant autoimmune enteropathy can 
be recognized in patients with genetically determined 
lack of specific immune regulatory mechanisms causing 
uncontrolled self-tissue aggression or uncontrolled 
inflammation (Table 4).
IPEX syndrome
IPEX syndrome is the prototype genetic autoimmune 
enteropathy. It is due to a mutation in the FOXP3 gene, 
which is an essential transcription factor for thymic-
derived regulatory T (TREG) cell function.42 FOXP3+ 
TREG cells are one of the main subset of CD4+ TREG cells, 
and are able to control undesirable effector-T-cell func-
tion. FOXP3 mutations are distributed throughout the 
gene and are loss-of-function. As a consequence, TREG 
cells with mutated FOXP3 normally differentiate in the 
thymus and can be detected in the peripheral blood and 
tissues of patients with IPEX but are unable to suppress 
effector T cells. The early neonatal onset and severity 
of IPEX enteropathy suggests that the damage is prob-
ably already established during fetal life, independent of 
external environmental factors, such as nutrients and 
gut microbiota. In addition to the intestinal architectural 
changes, anti-harmonin antibodies are uniquely found 
in IPEX and have high diagnostic value.43 Harmonin is 
a scaffold protein expressed by intestinal epithelial cells, 
but why it is specifically targeted in patients with IPEX 
syndrome and not in patients with similar enteropathies 
and wild-type FOXP3, still has to be clarified. However, 
autoantibodies against target organs are abundant in 
patients with IPEX, in whom TREG-cell dysfunction is 
also associated with an increased number of autoreac-
tive B cells owing to altered peripheral B-cell tolerance 
influencing the production of autoantibodies.44
As well as being essential for TREG-cell function, FOXP3 
is also transiently expressed by any activated T cells, in 
which it controls the cell cycle and development of T 
helper (TH) cells.45 This factor adds further complexity to 
the pathogenesis of IPEX, in which intrinsic impairment 
of the FOXP3 mutant effector-T-cell functions should be 
considered. Indeed, patients with IPEX manifest lym-
phoproliferation, a higher frequency of TH2 over TH1 
cells and increased levels of peripheral T cells producing 
Table 4 | Defects in intestinal immune-related homeostasis: genetics and epidemiology
Disease Inheritance and
incidence
Gene
(OMIM number)
Impaired biological activity causing diarrhoea 
and involved protein
Early onset 
enteropathy with 
colitis
AR 
Few cases described
IL10 (124092) Altered IL-10 or its receptor subunits involved in the 
control of intestinal microbial stimulations
IL10RA (146933)
IL10RB (123889)
IPEX syndrome X-linked 
Few hundred cases described
FOXP3 (300292) Impaired activity of forkhead box P3 involved in the 
development of CD4+CD25+ TREG cells
IPEX-like disorders AR 
Few cases described
CD25 (147730) Impaired synthesis of α chain of IL-2 receptor on 
TREG cells
AR 
Few cases described
STAT5B (604260) Impaired activity of signal transducer and activator of 
transcription 5b involved in IL-2 signalling in TREG cells
AD 
Few cases described
STAT1 (600555) Enhanced or reduced activity of signal transducer and 
activator of transcription 1 causes the reprograming of 
TREGcells into TH1-like cells
AR 
One family described
ITCH (606409) Altered activity of ITCHY E3 ubiquitin ligase implicated 
in the development of TREG cells
AR 
Three families described
LRBA (606453) Impaired activity of lipopolysaccharide-responsive 
beige-like anchor protein stimulates apoptosis of TREG cells
Abbreviations: AD, autosomal dominant; AR, autosomal recessive; IPEX, immune dysregulation polyendocrinopathy enteropathy X-linked; TH1, type 1 T helper cell; 
TREG, regulatory T cell.
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IL-17, a proinflammatory cytokine frequently reported in 
autoimmune diseases. Interestingly, mucosa lymphocyte 
infiltration in IPEX is predominantly by CD4+ T cells, 
some of which express FOXP3.44 Gut-infiltrating lym-
phocytes, isolated from biopsy samples of patients with 
IPEX and expanded in vitro, are enriched with IL-17-
producing cells that co-express FOXP3 (Passerini L. 
and Bacchetta R. unpublished data). These cells could 
have a direct role in gut damage, whether they are acti-
vated effector T cells producing IL-17 or TREG cells that, 
because of the FOXP3 mutation, are unstable and gain 
effector functions.
Lentiviral-mediated overexpression of wild-type 
FOXP3 successfully conveys stable regulatory function 
to FOXP3 mutant T cells,44 opening new therapeutic 
perspectives for patients with IPEX. Several patients 
with IPEX have been cured with haematopoietic stem 
cell transplantation,46 but this approach is preferentially 
feasible in children with HLA-matched donors (which 
are not always available). Gene correction of autologous 
stem cells will hopefully become an option for patients 
with IPEX. Other therapeutic approaches—that is, alter-
natives to multiple immunosuppression—could also be 
envisaged, aiming to re-establish tolerance in a FOXP3-
independent manner. For example, IL-10 dependent 
type 1 regulatory T (Tr1) cells—which have an impor-
tant role in peripheral regulation—can differentiate 
in patients with IPEX despite the presence of FOXP3 
mutation; therefore, therapeutic interventions facilitat-
ing Tr1 differentiation that could restore immunoregula-
tion and antagonize inflammation could be envisaged. 
Interestingly, patients with IPEX who have their FOXP3 
mutations diagnosed late and with unusual clinical pres-
entation, such as gastritis or nephropathy, have been 
reported.47,48 Whether this different phenotype is due 
to the presence of hypomorphic mutation with residual 
protein function or due to the presence of more efficient 
FOXP3-independent compensatory mechanisms of 
t olerance remains to be clarified.
IPEX-like syndromes
These conditions are associated with mutations in genes 
other than FOXP3 that are important for TREG-cell main-
tenance, signalling and expansion.49 Mutations in CD25 
are responsible for early-onset enteropathy resembling 
IPEX with autosomal recessive inheritance. Given that 
interleukin-2 receptor subunit alpha (also known as 
CD25; encoded by CD25) is essential not only for TREG-
cell function but also to mount an appropriate immune 
response, these patients also have an impaired ability 
to fight infections; the early-onset enteropathy in these 
patients might be due to Cytomegalovirus infection, con-
comitant with the immune dysregulation. The majority 
of patients with an IPEX-like syndrome, however, lack 
a clear diagnosis of the underlying mechanism of their 
disease. In at least a group of these patients, a quantitative 
defect in FOXP3+ TREG cells is detected by measuring the 
peripheral percentage of the TREG-specific DNA demethy-
lated region (TSDR) of FOXP3, but the u nderlying gene 
defects still has to be determined.
Mutations in STAT5B, responsible for transactiva-
tion of the IL-2 signal from CD25 to FOXP3, have been 
described associated with reduced number of TREG cells.49 
Children with STAT5B (signal transducer and activator 
of transcription 5b) mutation have symptoms other than 
enteropathy, such as growth failure and interstitial lung 
disease, that can help in establishing the diagnosis. Early-
onset chronic or recurrent enteropathy has also been 
reported in patients with either loss-of-function or gain-
of-function mutations in STAT1, which also impinges 
effective immunity.50 Infections and progressive loss of 
T cells (both in terms of number and function, including 
TREG cells) is reported in patients with loss-of-function 
mutations, whereas TREG-cell instability has been sug-
gested as a consequence of the gain-of-function variants, 
which is characterized by chronic mucocutaneous can-
didiasis.49 A more predominant inflammatory imbalance 
has been described in an extended family with recur-
rence of lymphoproliferation, inflammation and dys-
morphisms, due to mutation in ITCH, which encodes an 
ubiquitin ligase implicated in several T-cell functions.49
An IPEX-like disorder (characterized by diarrhoea) with 
profound TREG-cell deficiency but a normal FOXP3 gene 
sequence has been described with homozygous nonsense 
mutation in the LRBA (lipopolysaccharide-responsive 
and beige-like anchor) gene.51,52 Patients with LRBA muta-
tions were previously reported to have common vari-
able immuno deficiencies phenotype and autoimmunity.51 
Analysis of other patients with LRBA deficiency clearly 
revealed TREG-cell deficiency, decreased TREG-cell markers, 
and impaired suppressive function of TREG cells.52
IL-10 or IL10R deficiency
IL-10 or IL-10 receptor (IL-10R) response insufficiency 
is characterized by enterocolitis with ulcerative lesions 
in the perianal area and in the intestinal mucosa.53 
Fistula and abscesses can also be present, with recur-
rence requiring multiple surgical interventions. Gene 
mutations in either IL10RB or IL10RA (interleukin-10 
receptor subunit alpha or beta) abrogate response to 
IL-10, causing persistent colonic inflammation.54 Lack 
of STAT3 phosphorylation in response to IL-10 can be 
detected in vitro and used as a first indication of the 
disease cause.55 Several anti-inflammatory drugs have 
been used, but pharmacological approaches only have 
limited efficacy. Haematopoietic stem cell transplanta-
tion has been used successfully to cure the disease.56 
Although studies of Tr1 cells in these patients have not 
been directly performed, these disorders illustrate the 
essential role of IL-10 in controlling intestinal homeo-
stasis.57 Interestingly, independent genome studies have 
demonstrated attenuated mutations in IL-10, IL10RA, 
IL10RB or in FOXP3 in a few rare patients with IBD. This 
confirms the nonredundancy of both regulatory path-
ways in the intestine and the importance of considering 
genetic screening in the presence of early-onset disease.57
Molecular diagnostics
In the past decade, the genes responsible for most CDDs 
have been identified (Tables 1–4). The availability of DNA 
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sequencing techniques, at reasonable cost, has greatly 
improved the diagnostic approach to these conditions 
through the search for DNA mutations in samples from 
blood cells or from amniocytes and chorionic villi (prena-
tal diagnosis). Molecular genetics has become helpful to 
obtain early and unequivocal diagnoses in patients at an 
age in which chronic diarrhoea might be due to a myriad 
of different disorders, thus permitting rapid and targeted 
therapeutic strategies58 and reducing repetitive invasive 
and expensive procedures. Furthermore, the identification 
of disease-causing mutations in the affected proband along 
with family counselling can help to reveal asymptomatic 
carriers and to offer future prenatal diagnosis.59
Whether the type of mutation(s) can provide guidance 
as to the severity of the clinical phenotype is still under 
discussion. In selected CDDs, such as congenital chloride 
diarrhoea, the clinical expression is poorly related to the 
genotype and modifier genes might contribute to mod-
ulate the phenotype. However, genotype might predict 
response to therapy. For example, it has been demon-
strated that specific SLC26A3 mutations that retain at 
least some activity of the protein could predict a more 
pronounced effect of oral butyrate therapy.60
Although molecular genetics represents a relevant 
contribution to the multistep diagnostic approach to 
CDDs, some critical points need to be discussed. In most 
genes responsible for CDDs, mutations are detectable 
throughout the gene—with the exception of a few con-
ditions, such as congenital chloride diarrhoea, congeni-
tal lactase deficiency, sucrose-isomaltase deficiency and 
MVID, in which, in some specific ethnic groups, only a 
few mutations are implicated owing to a founder effect.1 
This finding suggests that sequencing analysis of the 
whole coding region of the gene must be used to obtain 
a satisfactory detection rate. For most CDDs, sequenc-
ing of the whole coding region of the gene is needed to 
detect mutation(s) in up to 90% of affected alleles, but a 
few alleles remain uncharacterized. However, sequencing 
frequently reveals novel mutations and in some cases (for 
example, missense mutations) it might be difficult to be 
certain of their pathogenic effect, hampering our ability 
to provide family counselling with certainty. In these 
cases, international repositories of mutations might help 
laboratories involved in performing molecular genetics, 
but such databases are not available for all CDDs. Data 
obtained in large series of healthy individuals from the 
same ethnic group might help to elucidate if a genetic 
variant is a benign polymorphism with a high frequency 
in the general population. The 1000 Genomes Project61 
will address some of these concerns. More complex 
in vitro functional studies are required to assess the effect 
of mutations of uncertain clinical significance, but such 
studies are rarely performed in a routine setting.
Conclusions
We are observing a substantial improvement in under-
standing the evolving web of CDDs. Major advances have 
been made in terms of pathogenesis, enabling a better 
understanding not only of these rare conditions but also 
of more common diseases. Although the list of CDDs is 
continuously expanding, findings from both experimen-
tal models and human data are leading to improved diag-
nostic and therapeutic strategies (Box 1). Development 
of a procedure to propagate 3D ‘enteroids’ from human 
intestinal stem cells is providing exciting new research 
perspectives for research and therapy by increasing our 
understanding of human intestinal pathophysiology, 
developmental biology and regenerative medicine.62 
A 3D culture of intestinal stem cells (organoids) derived 
from duodenal biopsy specimens from patients with 
MVID has been developed, which recapitulates most 
typical morphological features of the disease.5
Molecular genetics will further change the diagnostic 
scenario in CDDs. The availability of massive sequenc-
ing techniques is leading to the identification of novel 
disease-genes, improving our understanding of the 
pathophysiology of CDDs and the development of 
targeted therapies. Indeed, haematopoietic stem cell 
transplantation is becoming a valid therapeutic option 
for several defects in intestinal immune-related homeo-
stasis.63 Novel gene therapy approaches using homing 
endo nucleases, including TALENs (transcription activa-
tor-like effector nucleases) or CRISPR/Cas9 (clustered 
regularly interspaced short palindromic repeats/CRISPR 
associated protein 9), or other technologies could also be 
pursued.64 Furthermore, sequencing will be extended to 
noncoding, regulatory regions of disease-genes such as 
the promoter,65 introns and the 3` untranslated regions,66 
increasing the detection rate of mutations and opening 
up the possibility of further molecular therapies.67
Long-term studies should be encouraged to provide 
more insights on the prognosis of these conditions. For 
example, in CTE an increased chance of weaning off par-
enteral nutrition with increasing age has been demon-
strated—ranging from 10% chance at the age of 10 years 
to 40% at the age of 10–20 years.68 This finding suggests 
that intestinal transplantation should be avoided if pos-
sible. Given the number of CDDs, the complexity of 
Box 1 | Treatments for congenital diarrhoeal disorders
Defects in absorption and transport of nutrients and 
electrolytes
 ■ Nutrition therapy (exclusion diet, special formulae)
 ■ Substitutive therapy (salts, Zn2+)
 ■ Parenteral nutrition
Defects in enterocyte structure
 ■ Total parenteral nutrition
 ■ Antisecretory drugs
 ■ Intestinal transplantation
Defects in enteroendocrine cell differentiation
 ■ Total parenteral nutrition that can be weaned beyond 
2 years of age
Defects in intestinal immune-related homeostasis
 ■ Total parenteral nutrition and hormone replacement 
therapy
 ■ Immunosuppressive and immunomodulatory 
drugs (corticosteroids, cyclosporine, azathioprine, 
6-mercaptopurine, tacrolimus, mycophenolate mofetil, 
sirolimus, infliximab, rituximab) 
 ■ Bone marrow transplantation
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genotype–phenotype correlations and the need for multi-
disciplinary counselling to families, a strict collaboration 
between physicians and molecular laboratories within 
international networks could be useful to limit the crea-
tion of orphan diseases. Some examples of this are the 
MVID Patient Registry69 (dedicated to all clinicians and 
scientists working in the fields of MVID and the MY05B 
gene), the Congenital Diarrheal Disorders website70 and 
the IPEX syndrome consortium,71 with the aim of provid-
ing rapid access to molecular analysis and other diagnostic 
procedures for patients with suspected CDDs.
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